Navigation Links
VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
Date:6/4/2009

ervations suggest DGAT1 inhibitors may have the potential to treat obesity, diabetes and dyslipidemia. VIA intends to identify potential clinical candidates from the compounds in this program and determine whether any can be moved into further preclinical development.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in plaque, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit: http://www.viapharmaceuticals.com.

Forward Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements si
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
2. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
4. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
5. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
6. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
7. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
8. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
9. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
10. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
11. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Bill Jacobs Automotive, a group of car dealerships ... with the Heartland Blood Center and offering free oil change ... takes place Saturday, Jan. 18 at the Bill Jacobs Cadillac ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  The Bill ...
(Date:1/15/2014)... 15, 2014   Niagara Thermal Products is proud ... BioBlower Technologies LLC ("B3") as the critical thermal component ... from the Army Corps of Engineers.  B3 has developed ... biological contaminants and destroys VOCs and other chemical pollutants, ...
(Date:1/15/2014)... Westlake Village, Calif. (PRWEB) January 15, 2014 ... cancer treatment and management through the genomic analysis of ... will offer Therapy Finder™, a web-based cancer decision support ... a reporting option with Cynvenio’s ClearID™ genomic test, Therapy ...
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer ... EmblemHealth , the New York ... the RedBrick Compass health assessment, combined with the RedBrick ... members. EmblemHealth is among the first health plans in ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3
... Corporation, an,orthopedic implants company focused on silicon nitride ... Drug Administration,has granted 510(k) marketing clearance to Amedica,s ... system is a low profile and modular pedicle,screw ... surgeons,greater flexibility in the positioning of these spinal ...
... Daval International Limited, a UK,private company, ... of a,London based Phase IIB trial of ... double-blind placebo-controlled cross-over study will seek to,detect ... patients with Secondary,Progressive Multiple Sclerosis, following open-label ...
... 26 H2Diesel Holdings, Inc. (OTC,Bulletin Board: HTWO) today ... Officer, effective December 1, 2007., Since 2004, Mr. ... Inc. where he led the Company,s finance and,information technology ... Chairman of the Board and CEO. From 2001 to ...
Cached Biology Technology:Amedica Receives FDA 510(k) Clearance for Valeo(TM) Pedicle Screw System 2H2Diesel Announces Appointment of Cary J. Claiborne as Chief Financial Officer 2H2Diesel Announces Appointment of Cary J. Claiborne as Chief Financial Officer 3
(Date:7/9/2014)... pain and fever but often can be defeated with antibiotics ... hard to beat. Now, scientists have built a new weapon ... Published in the journal ACS Applied Materials & Interfaces ... kill more of them than medicine alone. , David Leong, ... lie in wait, undetectable in the human body or in ...
(Date:7/9/2014)... U.S. may be on the verge of an economy driven ... cleaner than coal and is undergoing a production boom. It ... but recent research is casting serious doubts over just how ... & Engineering News (C&EN), the weekly news magazine of ... a senior correspondent at C&EN, explains that when burned as ...
(Date:7/9/2014)... results accrue. To completely and systematically archive this ... fact, researchers in the life sciences spend a ... an online survey of 70 people working in ... Applied Information Technology FIT in Sankt Augustin. Many ... centralized or structured approach to data collection in ...
Breaking Biology News(10 mins):Managing the data jungle 2Managing the data jungle 3
... Hopkins Bloomberg School of Public Health and the Chronic Kidney ... complications were associated with a higher risk of death regardless ... American Society of Nephrology conference in San Diego, Ca. and ... kidney disease prevalence increases dramatically with age from 4 percent ...
... Oct. 31As a human fetus develops, its heart has to ... this is controlled by following genetic blueprints, but the embryonic ... pumping blood. For the first time, researchers have been able ... in an embryonic heart. The technique, which promises to provide ...
... know their friends," wrote Shakespeare. In humans, nature may be ... University of Colorado Boulder researchers has found. In the ... similarities may help to explain why human birds of a ... become friends "is contingent upon the social environment in which ...
Cached Biology News:Chronic kidney disease increases risk of death at all ages 2First-ever 3-D stress map of developing embryonic heart sheds light on why defects form 2Social factors trump genetic forces in forging friendships, CU-led study finds 2
... Escherichia coli RY 13 5'G AATTC3' 3'CTTAA G5' ... min or ethanol precipitation. Storage Conditions: 10mM Tris-HCl ... 0.15% Triton X-100, 0.01% BSA, 50% glycerol. Shipping ... -20C. Unit Definition: One unit is defined as ...
... LabWorks Software provides a comprehensive experiment based ... drop down menus yet sophisticated and powerful ... dozens of CCD cameras for easy image ... , Automated Digital Video Playback ...
... Heavy duty stainless-steel shaker flask clips, purpose-designed ... speeds. All clips are equipped with ... 1L.) also include a bottom retainer spring, ... scratching of expensive glassware. Clips include ...
... mix (Thermoprime Plus DNA Polymerase with a ... times higher fidelity than standard Taq DNA ... DNA polymerase, Amplifies DNA templates >20kb, Concentration: ... PCR for cloning and mutagenesis We are ...
Biology Products: